

Rachel R Kroe-Barrett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7857340/publications.pdf>

Version: 2024-02-01

24
papers

680
citations

687363

13
h-index

642732

23
g-index

24
all docs

24
docs citations

24
times ranked

1221
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of the ADCC-Modulating Mutations and the Selection of Human IgG Isotypes on Physicochemical Properties of Fc. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2411-2421.	3.3	0
2	Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 96-108.	4.1	15
3	A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2250-2261.	4.1	11
4	An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases. <i>International Journal of Pharmaceutics</i> , 2021, 609, 121162.	5.2	6
5	VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis. <i>MAbs</i> , 2020, 12, 1709322.	5.2	24
6	X-ray crystal structure localizes the mechanism of inhibition of an IL-36R antagonist monoclonal antibody to interaction with Ig1 and Ig2 extra cellular domains. <i>Protein Science</i> , 2020, 29, 1679-1686.	7.6	3
7	Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5). <i>MAbs</i> , 2019, 11, 956-964.	5.2	7
8	IgG Charge: Practical and Biological Implications. <i>Antibodies</i> , 2019, 8, 24.	2.5	54
9	Weak IgG self- and hetero-association characterized by fluorescence analytical ultracentrifugation. <i>Protein Science</i> , 2018, 27, 1334-1348.	7.6	27
10	Optimizing NBE PK/PD assays using the Gyrolab Affinity Software; conveniently within the bioanalyst's existing workflow. <i>Bioanalysis</i> , 2018, 10, 397-406.	1.5	4
11	Non-neutralizing antibodies increase endogenous circulating Ang1 levels. <i>MAbs</i> , 2018, 10, 1260-1268.	5.2	4
12	Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 19-24.	2.1	37
13	Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies. <i>MAbs</i> , 2017, 9, 1143-1154.	5.2	69
14	Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	17
15	Maximizing <i>in vivo</i> target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn. <i>MAbs</i> , 2017, 9, 1105-1117.	5.2	22
16	IgG cooperativity – Is there allostery? Implications for antibody functions and therapeutic antibody development. <i>MAbs</i> , 2017, 9, 1231-1252.	5.2	52
17	Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics. <i>Analytical Biochemistry</i> , 2016, 508, 78-96.	2.4	92
18	Efficient Qualitative and Quantitative Determination of Antigen-induced Immune Responses. <i>Journal of Biological Chemistry</i> , 2016, 291, 16361-16374.	3.4	13

#	ARTICLE	IF	CITATIONS
19	Dataset of the binding kinetic rate constants of anti-PCSK9 antibodies obtained using the Biacore T100, ProteOn XPR36, Octet RED384, and IBIS MX96 biosensor platforms. <i>Data in Brief</i> , 2016, 8, 1173-1183.	1.0	7
20	Biophysical Techniques for Characterizing the Higher Order Structure and Interactions of Monoclonal Antibodies. <i>ACS Symposium Series</i> , 2015, , 285-327.	0.5	21
21	Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1. <i>MAbs</i> , 2015, 7, 1072-1083.	5.2	32
22	Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. <i>MAbs</i> , 2015, 7, 778-791.	5.2	92
23	Competing aggregation pathways for monoclonal antibodies. <i>FEBS Letters</i> , 2014, 588, 936-941.	2.8	64
24	Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activity. <i>Human Antibodies</i> , 2011, 20, 83-94.	1.5	7